---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-106464"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2024-09-13T23:59:59+00:00"
generated_at: "2026-05-31T04:58:06.855695+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tivic Health enters ATM equity facility up to $10M; appoints Lisa Wolf as interim CFO

## Summary
- Equity Distribution Agreement with Maxim Group for at-the-market sales of common stock up to $10M aggregate offering price; current baby shelf limit $1.44M.
- Maxim receives 3.0% commission; Tivic reimburses up to $40K expenses plus $5K per bringdown.
- Kimberly Bambach resigns as interim CFO effective Oct 1, 2024; remains advisor for strategic transactions.
- Lisa Wolf appointed interim CFO effective Oct 1, 2024; paid $275/hour as non-employee consultant; has served Tivic since June 2022 via Murdock Martell.
- Wolf brings 30 years experience, including CAO at Resonant (RESN) and CPA at Arthur Andersen.

## SEC filing metadata
- accession: 0000950170-24-106464
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2024-09-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017024106464/0000950170-24-106464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017024106464/tivc-20240912.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-106464
- JSON: https://secwatch.observer/filing/0000950170-24-106464.json
- Plain text: https://secwatch.observer/filing/0000950170-24-106464.txt

## Key facts
- Executive change
  Kimberly Bambach departed as interim Chief Financial Officer at Valion Bio, Inc..
  - Action: resignation
  - Role: interim Chief Financial Officer
  source text: On September 12, 2024, Kimberly Bambach tendered her resignation from her role as interim Chief Financial Officer of the Company, effective October 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000095017024106464/0000950170-24-106464-index.htm
- Executive change
  Lisa Wolf was appointed as interim Chief Financial Officer and Principal Financial and Principal Accounting Officer at Valion Bio, Inc..
  - Action: appointed
  - Role: interim Chief Financial Officer and Principal Financial and Principal Accounting Officer
  source text: Effective October 1, 2024, Lisa Wolf has been appointed as the Company’s new interim Chief Financial Officer and Principal Financial and Principal Accounting Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000095017024106464/0000950170-24-106464-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.